Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > Reading news...
View:
Post by wendhie05 on Apr 09, 2021 2:33am

Reading news...

I'm currently reading the news and one thing just pop up into my mind. "WHAT F*CK!"
Comment by wendhie05 on Apr 09, 2021 2:35am
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting
Comment by wendhie05 on Apr 09, 2021 2:36am
TORONTO, April 5, 2021 /PRNewswire/ - On Tuesday, March 30, 2021, Anthony Durkacz, a founding director and member of the group of concerned shareholders, which also includes founding shareholder Zeeshan Saeed, (the "Concerned Shareholders") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (the "Company" or "FSD") received a Notice ...more  
Comment by wendhie05 on Apr 09, 2021 2:37am
The Decision, which resulted from an application to the Court brought by Mr. Durkacz on behalf of the Concerned Shareholders, ordered the Company to accelerate the date of its previously called annual shareholders' meeting (the "Meeting") from June 29, 2021 to May 14, 2021, retain an independent chair to preside over the Meeting and prevent Dr. Raza Bokhari  ...more  
Comment by wendhie05 on Apr 09, 2021 2:38am
Among other things, FSD's Appeal is seeking to delay the date of the Meeting to June 29, 2021 and remove voting restrictions that the Order attached to shares issued since January 4, 2021 to Dr. Raza Bokhari, Stephen Buyer, Robert Ciaruffoli, James Datin, Gerald Goldberg and Larry Kaiser and any entities related to any of them.
Comment by wendhie05 on Apr 09, 2021 2:39am
"This is an entirely unjustified waste of FSD's money," said Anthony Durkacz, one of the Concerned Shareholders. "FSD management resisted our proposed shareholder meeting date of March 31, 2021 on the basis that the company needed to receive its audited financial statements for the 2020 financial year and wanted to avoid the expense of holding two meetings. 
Comment by wendhie05 on Apr 09, 2021 2:40am
These concerns have been fully-accommodated - FSD's auditors have already delivered the audited financial statements and a single meeting is being held on May 14, 2021. This appeal is a waste of money and another attempt by FSD management to delay being held accountable to FSD's shareholders."
Comment by wendhie05 on Apr 09, 2021 2:42am
The absurdity of this legal maneuver is evident in the fact that the appeal is scheduled to be held on May 3, 2021 – only 11 days before the Meeting and at least 10 days after FSD will have been required by securities and corporate laws to prepare and mail a circular for the Meeting to shareholders. 
Comment by wendhie05 on Apr 09, 2021 2:43am
Delaying the Meeting would require FSD to prepare and mail a second circular – causing it to unnecessarily incur the duplicate meeting expenses it previously sought to avoid by accepting a meeting date in May rather than the earlier date requested by the Concerned Shareholders. This is a clear case of Raza Bokhari and the directors who support him inflicting unnecessary expense on the ...more  
Comment by wendhie05 on Apr 09, 2021 2:44am
Mr. Durkacz added, "In February 2021, Raza Bokhari and the other directors awarded themselves inflated compensation of approximately C$6.7 million for services not yet provided. The longer they delay the meeting, the more they earn. This appeal only serves the interests of Raza Bokhari and the directors who support him and has no value for other shareholders ...more  
Comment by wendhie05 on Apr 09, 2021 2:49am
On May 14, 2021, shareholders will have the opportunity to put FSD back on the path to success. Mr. Durkacz encourages shareholders to stay informed and exercise their rights at the Meeting, saying, "Shareholders have a right to determine the future of our company and these outrageous efforts by Dr. Raza Bokhari and other directors to frustrate that only reinforces the urgent ...more  
Comment by wendhie05 on Apr 09, 2021 2:50am
Further details regarding the Concerned Shareholders' nominees and the reasons that the Concerned Shareholders want to reconstitute FSD's board are contained in the information circular available on the Company's SEDAR profile at www.sedar.com and at the website established by the Concerned Shareholders: www.RestoreFSD.com. Stay up-to-date by following us at:  ...more  
Comment by wendhie05 on Apr 09, 2021 2:51am
Follow FSD Pharma to be updated of what's happening in the company.
Comment by mhaimillionaire on Apr 09, 2021 2:03pm
I grabbed more shares! Worth to invest. A company that gives us assurance and guarantee.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities